An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice
Kathryn M Kinross, Karen G Montgomery, Margarete Kleinschmidt, Paul Waring, Ivan Ivetac, Anjali Tikoo, Mirette Saad, Lauren Hare, Vincent Roh, Theo Mantamadiotis, Karen E Sheppard, Georgina L Ryland, Ian G Campbell, Kylie L Gorringe, James G Christensen, Carleen Cullinane, Rodney J Hicks, Richard B Pearson, Ricky W Johnstone, Grant A McArthur Show all
Journal of Clinical Investigation | AMER SOC CLINICAL INVESTIGATION INC | Published : 2012
Related Projects (2)
Awarded by NHMRC
Awarded by Association of International Cancer Research
We thank Kerry Ardley for animal experiments and the Peter Mac core histology and pathology facilities. This work was supported by the NHMRC (grant no. 628620 to W.A. Phillips and no. 566876 to G.A. McArthur and R.B. Pearson); the Association of International Cancer Research (no. 10-0052 to W.A. Phillips); Pfizer (grant to G.A. McArthur and R.J. Hicks); the Cancer Council Victoria and the Victorian Cancer Agency (grants to R.W. Johnstone); and the Victorian Breast Cancer Research Consortium, Australia (to I.G. Campbell and K.L. Gorringe). Researchers were funded by a Sir Edward Weary Dunlop Fellowship, Cancer Council of Victoria (to G.A. McArthur); research fellowships from the NHMRC (to R.B. Pearson and R.W. Johnstone); Cure Cancer Australia Foundation and Cancer Australia (to I. Ivetac); the Egyptian government and NHMRC (to M. Saad); Australian Postgraduate Research Awards (to L. Hare and G.L. Ryland); and the Swiss National Science Foundation (to V. Roh).